Diabetes. Diabetic nephropathy
Conditions
Interventions
Intervention 1: Magnesium supplement, each tablet contains 250 mg magnesium oxide, 1 time a day for 12 weeks. Intervention 2: Placebo, similar color, odor and appearance to magnesium supplement, 1 tim
Treatment - Drugs
Placebo, similar color, odor and appearance to magnesium supplement, 1 time a day for 12 weeks
Magnesium supplement, each tablet contains 250 mg magnesium oxide, 1 time a day for 12 weeks
Sponsors
Isfahan University of medical sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: More than 18 years old Diabetic nephropathy Blood glucose more than 126 milligram per decilite Proteinuria between 30 to 300 milligram per deciliter (micro-albuminuria) Glomerular Filtration Rate more than 90 milliliter per minute Not having hypothyroidism and hyperthyroidism; Not having any urine duct infection; Not having any feverish infection; Not using cigarette or other drugs; Not having liver disease; Not having cancer; Not having any inflammatory disease Not losing weight more than 4 kilogram during last 3 months Not using any magnesium-rich supplement
Exclusion criteria
Exclusion criteria: Changing medicine doses failure to adherence (using less than 75 percent of medicines)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Albumin to creatinine ratio (UACR). Timepoint: Baseline, week 12. Method of measurement: Commercial kit. | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood Urine Nitrogen. Timepoint: Baseline, week 12. Method of measurement: Commercial kits.;Glomerular Filtration Rate. Timepoint: Baseline, week 12. Method of measurement: commercial kits.;Proteinuria. Timepoint: Baseline, week 12. Method of measurement: Methyl benzatonium chloride method.;Fasting Blood Sugar. Timepoint: Baseline, week 12. Method of measurement: Commercial kits.;Hemoglubin A1c. Timepoint: Baseline, week 12. Method of measurement: High-Performance Liquid Chromatography.;Serum insulin. Timepoint: Baseline, week 12. Method of measurement: Enzyme-Linked Immunosorbent Assay.;High Density Lipoprotein. Timepoint: Baseline, week 12. Method of measurement: Commercial kits.;Low Density Lipoprotein. Timepoint: Baseline, week 12. Method of measurement: Commercial kits.;Very Low Density Lipoprotein. Timepoint: Baseline, week 12. Method of measurement: Commercial kits.;Triglyceride. Timepoint: Baseline, week 12. Method of measurement: Commercial kits.;Total Cholesterol. Timepoint: Baseline, week 12. Method of measurement: Commercial kits.;C-Reactive Protein. Timepoint: Baseline, week 12. Method of measurement: Enzyme-Linked Immunosorbent Assay.;Creatinine. Timepoint: Baseline, week 12. Method of measurement: Commercial kits. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAhmad Esmaeilzade
Isfahan University of Medical Sciences
Outcome results
None listed